Remove Angioplasty Remove Outcomes Remove Pulmonary
article thumbnail

Chronic Thromboembolic Pulmonary Hypertension: the therapeutic assessment

Frontiers in Cardiovascular Medicine

Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a severe and complex condition that evolves from unresolved pulmonary embolism, leading to fibrotic obstruction of pulmonary arteries, pulmonary hypertension, and potential right heart failure.

article thumbnail

Continuous heart monitoring to evaluate treatment effects in pulmonary hypertension

Open Heart

Background The treatment of pulmonary hypertension (PH) has improved rapidly in recent decades. There is increasing evidence to support the role of early intervention and treatment in affecting clinical outcomes in PH. Methods Patients were compared before and after treatment escalation.

article thumbnail

Patient-specific 3D in vitro modeling and fluid dynamic analysis of primary pulmonary vein stenosis

Frontiers in Cardiovascular Medicine

IntroductionPrimary pulmonary vein stenosis (PVS) is a rare congenital heart disease that proves to be a clinical challenge due to the rapidly progressive disease course and high rates of treatment complications. These 3D reconstructions were 3D printed using a clear resin ink and used in a benchtop experimental setup.

article thumbnail

Top Specialties in Fellowship Programs and What They Offer: An In-depth Look for Medical Professionals

ADN Center of Excellence

Our Interventional Cardiology Fellowship Program offers a unique opportunity for fellows to immerse themselves in high-volume centers and experience complex procedures such as angioplasties, stent placements, and Chronic Total Occlusion (CTO) interventions. Requirements This specialty requires a background in internal medicine or pediatrics.

Cancer 59
article thumbnail

BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

DAIC

a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial. Getty Images milla1cf Thu, 05/02/2024 - 10:12 May 2, 2024 — BioCardia, Inc. ,

article thumbnail

Stent‐in‐Stent Intervention for Pulmonary Vein in Stent Restenosis: A Long‐Term Follow‐Up Case Report

Journal of Cardiovascular Electrophysiology

ABSTRACT Introduction Pulmonary vein (PV) restenosis develops with reported incidence rates of up to 50%. Balloon angioplasty seems to be the widely preferred treatment of choice. Conclusion Our case demonstrates stenting as a viable alternative strategy with potentiallyfavorable long-term outcome.

Stents 40
article thumbnail

Abstract 4139207: Supraselective Administration of Very Low-dose Intracoronary Epinephrine as a Rescue and First-line Drug for the Management of No-reflow in Conjunction With the IIB-IIIA Inhibitor Tirofiban.

Circulation

to 10% of percutaneous coronary interventions (PCI), no-reflow is a complication associated with poor outcomes like myocardial infarction extension and death. However, one patient with LVEF 20% died of pulmonary edema 7 hours postangioplasty. Circulation, Volume 150, Issue Suppl_1 , Page A4139207-A4139207, November 12, 2024.